Results 31 to 40 of about 57,881 (149)

HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells. [PDF]

open access: yesPLoS Pathogens, 2014
Human Papillomavirus (HPV) 16 E7 protein promotes the transformation of HPV infected epithelium to malignancy. Here, we use a murine model in which the E7 protein of HPV16 is expressed as a transgene in epithelium to show that mast cells are recruited to
Anne-Sophie Bergot   +5 more
doaj   +1 more source

E6^E7, a Novel Splice Isoform Protein of Human Papillomavirus 16, Stabilizes Viral E6 and E7 Oncoproteins via HSP90 and GRP78

open access: yesmBio, 2015
Transcripts of human papillomavirus 16 (HPV16) E6 and E7 oncogenes undergo alternative RNA splicing to produce multiple splice isoforms. However, the importance of these splice isoforms is poorly understood.
Masahiko Ajiro, Zhi-Ming Zheng
doaj   +1 more source

High-Risk Human Papillomavirus Oncogenic E6/E7 mRNAs Splicing Regulation

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
High-risk human papillomavirus infection may develop into a persistent infection that is highly related to the progression of various cancers, including cervical cancer and head and neck squamous cell carcinomas.
Yunji Zheng   +3 more
doaj   +1 more source

Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells

open access: yesVirology, 2001
Therapeutic vaccines against tumors associated with human papillomaviruses (HPV) should elicit cellular immune responses against early HPV antigens, primarily the oncoproteins E7 and E6. Because of safety concerns, the direct use of an unmodified oncogene is impossible in human DNA vaccination.
Šmahel, Michal   +3 more
openaire   +2 more sources

Localisation of human papillomavirus 16 E7 oncoprotein changes with cell confluence. [PDF]

open access: yesPLoS ONE, 2011
E7 is one of the best studied proteins of human papillomavirus type 16, largely because of its oncogenic potential linked to cervical cancer. Yet the sub-cellular location of E7 remains confounding, even though it has been shown to be able to shuttle ...
Joanna Laurson, Kenneth Raj
doaj   +1 more source

Induced blue phase of cholesteric-nematic mixtures under the action of acetone vapors

open access: yesФізика і хімія твердого тіла
Liquid crystals can exhibit structural orientational order. The creation of a mixture with the addition of chiral molecules to the nematic liquid crystal induces helical twisting, the axis of which is directed perpendicular to the cell surfaces.
Z.M. Mykytyuk   +7 more
doaj   +1 more source

High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation

open access: yesmBio, 2016
The major transformation activity of the high-risk human papillomaviruses (HPV) is associated with the E7 oncoprotein. The interaction of HPV E7 with retinoblastoma family proteins is important for several E7 activities; however, this interaction does ...
Elizabeth A. White   +2 more
doaj   +1 more source

Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects. [PDF]

open access: yesPLoS ONE, 2013
INTRODUCTION: Human papillomavirus (HPV) has been consistently implicated in causing several kinds of malignancies, and two HPV oncogenes, E6 and E7, represent two potential target antigens for cancer vaccines.
Wen-Fang Cheng   +6 more
doaj   +1 more source

Production of Polyclonal Antibody to the HPV58 E7 Protein and Its Detection in Cervical Cancer.

open access: yesPLoS ONE, 2016
The persistent infection of high-risk human papillomavirus (HPV) is one of the most common causes of cervical cancer worldwide, and HPV type 58 is the third most common HPV type in eastern Asia.
Qiaoli Zheng   +9 more
doaj   +1 more source

The action with manifest E7 type symmetry [PDF]

open access: yesJournal of High Energy Physics, 2019
Abstract We generalize Cremmer-Julia 1st order action of $$ \mathcal{N}=8 $$ N = 8 supergravity with manifest E 7(7) symmetry to cases of $$ \
openaire   +3 more sources

Home - About - Disclaimer - Privacy